siRNA, Anti-MAP3K7, 2'-F/2'-OMe/2'-MOE/LNA/Ribo/Backbone-modified(CAT#: SIRGT21521WQ-2OMe)
The product SIRGT21521WQ-2OMe is a type of small interfering RNA (siRNA) that targets MAP3K7 gene and regulates the expression of gene. The siRNA interferes with the expression of MAP3K7 gene with complementary nucleotide sequences by degrading mRNA after transcription, preventing translation. The siRNA is designed with 2ʹ-O-methyl (2'-OMe) modification to provide increased stability, increased specificity and reduced immunogenicity. It has potential applications in RNA interference (RNAi) and gene therapy development.
| Specifications | |
|---|---|
| NCBI RefSeq | NM_003188.3; NM_145331.2; NM_145332.2; NM_145333.2 |
| Alternative Names | CSCF; FMD2; MEKK7; TAK1; TGF1a |
| Related Diseases | Cardiospondylocarpofacial Syndrome |
| Purification | HPLC |
| Sub Cat | Target | Species | Modification | Scale | |
|---|---|---|---|---|---|
| SIRGT22521WQ-2F | MAP3K7 | Human | 2ʹ-deoxy-2ʹ-fluoro (2'-F) | ||
| SIRGT23521WQ-2MOE | MAP3K7 | Human | 2'-O-methoxyethyl (2'-MOE) | ||
| SIRGT24521WQ-LNA | MAP3K7 | Human | Locked Nucleic Acid (LNA) | ||
| SIRGT21521WQ-RB | MAP3K7 | Human | Ribo-modified | ||
| SIRGT22521WQ-BB | MAP3K7 | Human | Backbone-modified |
